MedTrace Logo

Clinical Trials

NCT04799275 | ACTIVE_NOT_RECRUITING | PHASE2/PHASE3
422 participants

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2021-05-20
Completion:
2027-03-01
Conditions
  • Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
  • Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma
  • Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
  • Diffuse Large B-Cell Lymphoma Activated B-Cell Type
  • Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation
  • Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Grade 3b Follicular Lymphoma
  • HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
  • High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
  • High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • Intravascular Large B-Cell Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Nodular Lymphocyte Predominant B-Cell Lymphoma
  • Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
  • T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
  • Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
  • Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
  • PROCEDURE
  • DRUG
  • OTHER
  • BIOLOGICAL
No Results Yet
NCT04704661 | ACTIVE_NOT_RECRUITING | PHASE1
51 participants

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2021-08-09
Completion:
2027-03-31
Conditions
  • Advanced Breast Carcinoma
  • Advanced Colon Carcinoma
  • Advanced Colorectal Carcinoma
  • Advanced Endometrial Carcinoma
  • Advanced Gastric Carcinoma
  • Advanced Gastroesophageal Junction Adenocarcinoma
  • Advanced Malignant Solid Neoplasm
  • Advanced Salivary Gland Carcinoma
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Clinical Stage III Gastric Cancer AJCC v8
  • Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage IV Gastric Cancer AJCC v8
  • Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
  • HER2-Positive Breast Carcinoma
  • Malignant Hepatobiliary Neoplasm
  • Metastatic Breast Carcinoma
  • Metastatic Colon Carcinoma
  • Metastatic Colorectal Carcinoma
  • Metastatic Endometrial Carcinoma
  • Metastatic Gastric Carcinoma
  • Metastatic Gastroesophageal Junction Adenocarcinoma
  • Metastatic Malignant Solid Neoplasm
  • Metastatic Salivary Gland Carcinoma
  • Stage III Colon Cancer AJCC v8
  • Stage III Colorectal Cancer AJCC v8
  • Stage III Major Salivary Gland Cancer AJCC v8
  • Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
  • Stage IV Colon Cancer AJCC v8
  • Stage IV Colorectal Cancer AJCC v8
  • Stage IV Major Salivary Gland Cancer AJCC v8
  • Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
  • Unresectable Breast Carcinoma
  • Unresectable Colon Carcinoma
  • Unresectable Colorectal Carcinoma
  • Unresectable Endometrial Carcinoma
  • Unresectable Gastric Carcinoma
  • Unresectable Gastroesophageal Junction Adenocarcinoma
  • Unresectable Malignant Solid Neoplasm
  • Unresectable Salivary Gland Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT04692831 | ACTIVE_NOT_RECRUITING | PHASE1
60 participants

Testing a New Imaging Agent to Identify Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2020-11-30
Completion:
2026-11-30
Conditions
  • HER-2 Positive Malignant Carcinoma of Breast
  • HER-2 Protein Overexpression
  • HER2-positive Metastatic Breast Cancer
Interventions
  • COMBINATION_PRODUCT
No Results Yet
NCT04665739 | RECRUITING | PHASE2
70 participants

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2023-02-03
Completion:
2027-07-01
Conditions
  • Advanced Lung Neuroendocrine Tumor
  • Functioning Lung Neuroendocrine Tumor
  • Locally Advanced Lung Neuroendocrine Neoplasm
  • Lung Neuroendocrine Neoplasm
  • Lung Neuroendocrine Tumor G1
  • Lung Neuroendocrine Tumor G2
  • Metastatic Lung Neuroendocrine Neoplasm
  • Metastatic Lung Neuroendocrine Tumor
  • Non-Functioning Lung Neuroendocrine Tumor
  • Recurrent Lung Neuroendocrine Neoplasm
  • Unresectable Lung Neuroendocrine Neoplasm
  • Unresectable Lung Neuroendocrine Tumor
Interventions
  • PROCEDURE
  • DRUG
  • OTHER
No Results Yet
NCT04584255 | ACTIVE_NOT_RECRUITING | PHASE2
62 participants

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2020-12-18
Completion:
2025-07-01
Conditions
  • Stage I Breast Cancer
  • Stage II Breast Cancer
  • Stage III Breast Cancer
  • Breast Cancer
  • HER2-negative Breast Cancer
  • Germline BRCA1 Gene Mutation
  • Germline BRCA2 Gene Mutation
  • Deleterious PALB2 Gene Mutation
Interventions
  • DRUG
No Results Yet
NCT04576117 | ACTIVE_NOT_RECRUITING | PHASE3
300 participants

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2021-02-16
Completion:
2026-12-30
Conditions
  • Recurrent Low Grade Astrocytoma
  • Recurrent WHO Grade 2 Glioma
  • Refractory Low Grade Astrocytoma
  • Refractory Low Grade Glioma
  • Refractory WHO Grade 1 Glioma
Interventions
  • PROCEDURE
  • OTHER
  • DRUG
No Results Yet
NCT04550494 | RECRUITING | PHASE2
36 participants

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2021-04-26
Completion:
2026-12-01
Conditions
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Castration-Resistant Prostate Carcinoma
  • Clinical Stage III Gastric Cancer AJCC v8
  • Clinical Stage IV Gastric Cancer AJCC v8
  • HER2-Positive Breast Carcinoma
  • Locally Advanced Breast Carcinoma
  • Locally Advanced Gastric Carcinoma
  • Locally Advanced Malignant Solid Neoplasm
  • Locally Advanced Ovarian Carcinoma
  • Locally Advanced Pancreatic Carcinoma
  • Locally Advanced Prostate Carcinoma
  • Metastatic Breast Carcinoma
  • Metastatic Gastric Carcinoma
  • Metastatic Malignant Solid Neoplasm
  • Metastatic Ovarian Carcinoma
  • Metastatic Pancreatic Carcinoma
  • Metastatic Prostate Carcinoma
  • Platinum-Sensitive Ovarian Carcinoma
  • Recurrent Breast Carcinoma
  • Recurrent Gastric Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Pancreatic Carcinoma
  • Recurrent Prostate Carcinoma
  • Stage II Pancreatic Cancer AJCC v8
  • Stage III Ovarian Cancer AJCC v8
  • Stage III Pancreatic Cancer AJCC v8
  • Stage III Prostate Cancer AJCC v8
  • Stage IV Ovarian Cancer AJCC v8
  • Stage IV Pancreatic Cancer AJCC v8
  • Stage IV Prostate Cancer AJCC v8
Interventions
  • PROCEDURE
  • DRUG
No Results Yet
NCT04539366 | SUSPENDED | PHASE1
67 participants

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2022-01-25
Completion:
2040-12-31
Conditions
  • Recurrent Childhood Neuroblastoma
  • Recurrent Childhood Osteosarcoma
  • Recurrent Neuroblastoma
  • Recurrent Osteosarcoma
  • Refractory Childhood Neuroblastoma
  • Refractory Childhood Osteosarcoma
  • Refractory Neuroblastoma
  • Refractory Osteosarcoma
Interventions
  • BIOLOGICAL
  • PROCEDURE
  • OTHER
  • DRUG
No Results Yet
NCT04394858 | ACTIVE_NOT_RECRUITING | PHASE2
46 participants

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2021-03-17
Completion:
2028-03-01
Conditions
  • Advanced Adrenal Gland Pheochromocytoma
  • Advanced Paraganglioma
  • Metastatic Adrenal Gland Pheochromocytoma
  • Metastatic Paraganglioma
  • Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8
  • Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8
  • Unresectable Adrenal Gland Pheochromocytoma
  • Unresectable Paraganglioma
Interventions
  • PROCEDURE
  • DRUG
  • OTHER
No Results Yet
NCT04317105 | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2
54 participants

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2020-07-17
Completion:
2025-10-01
Conditions
  • Advanced Malignant Solid Neoplasm
  • Metastatic Malignant Solid Neoplasm
  • Unresectable Malignant Solid Neoplasm
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page